Will the FDA approve camizestrant for advanced breast cancer?
1.0 pts (24h)Health & MedicineOne-Off2m
KalshiComprobar disponibilidadKYC requerido2% de comisiónDatos de resolución verificadosCalibración aproximadaProbabilidad implícita actualBefore Jan 1, 2028 77%Líder entre 5 opciones
Calidad del mercado
45 / 100
Baja calidadVolumen 24h
47 €
Liquidez
3,9 mil €
Liquidez mediaCompra / Venta
32.0% / 37.0%
Spread
5.0 pt
Spread moderadoDatos de mercado
Actualizado hace 13 minutos
14 may 26, 2:001 oct 26, 3:59
Tendencias
Solo fondos simulados, sin dinero realNo es asesoramiento financiero
Resultado elegido
Before Oct 1, 202637%
Tendencia de volumen
$532 jul14d de datos28 jul
Mercados Relacionados
Will the FDA approve MDMA for PTSD?
0 €Before Jan 1, 2027: 10%KALSHI
KALSHI
Hantavirus pandemic in 2026?
97,7 mil €Sí: 3%
POLYMARKET
POLYMARKET
# of views of MrBeast video day 3?
6,5 mil €26-27M: 73%POLYMARKET
POLYMARKET
New pandemic in 2026?
5,2 mil €Sí: 9%POLYMARKET
POLYMARKET
Measles cases in 2026?
2,4 mil €Above 3000: 94%KALSHI
KALSHI
Pandemic in 2026?
2 mil €Sí: 6%KALSHI
KALSHIActivos en estos temas
Reglas
If the FDA approves camizestrant for HR+/HER2- advanced breast cancer with ESR1 mutation for marketing before Jun 1, 2026, then the market resolves to Yes.
- An approval is defined as:
- For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
- The following constitute approvals that trigger the Payout Criterion:
- Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs
- The following do NOT constitute approvals: